BIOMET RECONSTRUCTIVE DEVICE SALES JUMP 13%
This article was originally published in The Gray Sheet
Executive SummaryBIOMET RECONSTRUCTIVE DEVICE SALES JUMP 13%, outpacing the company's 10.7% gain for total sales in the first quarter. Sales of reconstructive devices, which consist primarily of products for knee, hip and shoulder replacement, were $56.1 mil. during the quarter. The company singled out its Maxim Total Knee System, saying that the product "continued to capture market share in the domestic total knee market."
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.